Respiratory Syncytial Virus Vaccines

Pfizer’s maternal vaccine against respiratory syncytial virus could significantly decrease clinical visits among infants and save more than $800 million in overall costs, according to a study presented at IDWeek.

The CDC last week recommended Pfizer’s respiratory syncytial virus vaccine for pregnant people to protect newborns from severe RSV illness.

Healio | Infectious Disease News Editorial Board Member Jeanne M. Marrazzo, MD, MPH, was appointed director of the National Institute of Allergy and Infectious Diseases, replacing Anthony S. Fauci, MD, who stepped down in December.

The CDC has recommended that infants be immunized with a monoclonal antibody against respiratory syncytial virus.

This coming fall and winter, older adults in the United States will face a decision: Should they roll up their sleeves to receive the world’s first approved vaccines against respiratory syncytial virus?

Moderna has initiated the rolling submission process for its respiratory syncytial virus vaccine candidate mRNA-1345, the company announced Wednesday.

The FDA has recently approved Pfizer’s respiratory syncytial virus vaccine, branded as Abrysvo, for adults aged 60 years or older.

The FDA this week approved Pfizer’s respiratory syncytial virus vaccine for adults aged 60 years or older — the second RSV vaccine approved for this population in the last month.

Respiratory syncytial virus, or RSV, showed signs of returning to its pre-pandemic seasonality this past winter, but researchers cautioned that off-season epidemics are still possible.

Moderna announced Tuesday that its RNA-based respiratory syncytial virus vaccine has met primary endpoints in a phase 3 trial showing that the vaccine is both safe and highly effective in older adults.